Interferon plus chemotherapy for primary treatment of ovarian cancer.
Berek
J S
JS
Division of Gynecologic Oncology, UCLA School of Medicine, Los Angeles, CA 90095-1740, USA.
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000276:immunology; D002455:Cell Division / Q000187:drug effects; D017326:Clinical Trials, Phase III as Topic; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000627:therapeutic use*; D009389:Neovascularization, Pathologic / Q000188:drug therapy; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000276:immunology; D016032:Randomized Controlled Trials as Topic
D000276:Adjuvants, Immunologic; D007371:Interferon-gamma